BMS 986465
Alternative Names: BMS-986465; TYK2i-CNSLatest Information Update: 25 Mar 2024
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple sclerosis
Most Recent Events
- 20 Feb 2024 Phase-I clinical trials in Multiple sclerosis (In volunteers) (PO) before February 2024 (NCT06144697) (Bristol-Myers Squibb pipeline, February 2024)
- 22 Nov 2023 Bristol-Myers Squibb plans a phase I trial (In volunteers) (NCT06144697)
- 14 Sep 2023 Preclinical trials in Multiple sclerosis in USA (PO) before September 2023